Experts name 2 star blue chip ASX 200 shares to buy now

These blue chip have been rated as buys…

| More on:
three businessmen high five each other outside an office building with graphic images of graphs and metrics superimposed on the shot.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

If you're looking to buy some ASX 200 blue chip shares, you may want to look at the stars named below.

Both have been tipped as buys with bright futures by top brokers. Here's why:

CSL Limited (ASX: CSL)

The first blue chip ASX 200 share that has been tipped as a buy is CSL.

It is one of the world's leading biotechnology companies and the name behind the CSL Behring, CSL Vifor, and Seqirus businesses.

CSL Behring is the global leader in a plasma therapies industry, CSL Vifor is a global leader in iron deficiency and iron deficiency anaemia therapies, and Seqirus is the number two player in the global influenza vaccines industry.

These businesses appear well-placed for growth thanks to their world class product portfolios, significant investment in research and development, and strong demand.

Morgans is positive on CSL and believes the tide is finally turning for the company after plasma collection headwinds eased. It said:

While near term challenges remain and plasma inventories will need to be rebuilt over time, strong plasma collection growth and ongoing demand across both Behring and Seqirus underpin strong growth and continued momentum.

Morgans has an add rating and $321.30 price target on its shares.

ResMed Inc (ASX: RMD)

Another star ASX 200 blue chip share that has need named as a buy is ResMed.

It is a global leader in the development, manufacturing, distribution, and marketing of medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders.

ResMed has been growing at a strong rate for years thanks to the popularity of its products and increasing demand for sleep treatment solutions.

Analysts at Goldman Sachs are very positive on the company and believe it is well-placed for further growth. It commented:

We continue to see a long-duration runway of HSD organic growth for RMD, and we believe that growth-adjusted valuation of 3.1x (sector 2.9x) is not demanding in the context of various near/long-dated tailwinds. Buy.

Goldman Sachs has a buy rating and $36.80 price target on its shares.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL Ltd. and ResMed Inc. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Blue Chip Shares

Person holding a blue chip.
Blue Chip Shares

2 ASX blue-chip shares I'd buy with $3,000 right now

These are large businesses with compelling futures.

Read more »

a man looks down at his phone with a look of happy surprise on his face as though he is thrilled with good news.
Blue Chip Shares

Why this could be one of the best blue chip ASX shares to buy right now

Morgans sees this blue chip as a best idea for investors right now.

Read more »

a man in a business suite throws his arms open wide above his head and raises his face with his mouth open in celebration in front of a background of an illuminated board tracking stock market movements.
Blue Chip Shares

Buy these ASX 200 blue chip shares for big returns

Analysts think these blue chips could be in the buy zone according to analysts.

Read more »

A couple are happy sitting on their yacht.
Opinions

Top ASX shares to buy instead of a term deposit in March 2024

You may have to weather the odd storm, but the long-term investment outlook looks fine!

Read more »

Happy woman looking for groceries. as she watches the Coles share price and Woolworths share price on her phone
Blue Chip Shares

Why Coles shares could be a best buy for blue chip investors

Bell Potter thinks Coles is the best supermarket to buy this month.

Read more »

Three excited business people cheer around a laptop in the office
Blue Chip Shares

2 powerful blue chip ASX 200 shares to buy for your portfolio

Analysts think these high-quality companies could give your portfolio a big boost.

Read more »

A little boy holds his fingers to his head posing as a bull.
Blue Chip Shares

Here are 2 high-quality ASX 200 blue chip shares that analysts are bullish on

These blue chips have been given a big thumbs up.

Read more »

Woman smiling with her hands behind her back on her couch, symbolising passive income.
Blue Chip Shares

This is the ASX blue-chip share I'd buy for dividend income

Here’s why I love this stock for payouts.

Read more »